C1-esterase inhibitor following cardiopulmonary bypass: evaluation of coagulation parameters

Abstract

This study was designed to evaluate the effects of C1-esterase inhibitor (C1-INH) on haemostasis and blood loss in routine cardiopulmonary bypass (CPB). To determine whether or not C1-INH reduces blood loss or transfusion requirements after routine CPB, we randomized 20 patients to receive double-blind either C1-INH (15 IU/kg over 10 minutes intravenously) or placebo following heparin administration. The two groups were similar in age, sex, prior salicylate use and time on CPB.

At 30 minutes from the beginning of CPB and postprotamine, factor XII, factor XI, C1-INH and prekallikrein activity were significantly higher (p < 0.05) than in the placebo group. No manifestations of hypercoagulability were seen in either group. Despite this haemostatic effect, patients treated with C1-INH had similar postoperative blood loss to the placebo group and similar blood transfusion requirements.

We conclude that routine use of C1-INH in CPB is unwarranted.

Get full access to this article

View all access options for this article.

References

Bick RL Haemostasis defects associated with cardiac surgery, prosthetic devices and other extracorporeal circuits. Semin Thromb Hemost 1985; 11: 249-80.

Harker LA Bleeding after cardiopulmonary bypass. N Engl J Med 1986; 314: 1446-48.

Brozivic M. Acquired disorder of coagulation. In: Bloom AL , Thomas DP eds. Haemostasis and thrombosis, second edition. Edinburgh: Churchill Livingstone, 1987: 519-34.

Mohe R. , Golan M. , Martinowitz U. et al. Effect of cardiac operations on platelets. J Thorac Cardiovasc Surg 1986; 92: 434-41.

Nilsson T. On the interaction between human plasma kallikrein and C1-esterase inhibitor . Thromb Haemost 1983;49:193-95.

Schreiber AD , Kaplan AP , Austen KF Inhibition by C1-INH of Hageman factor fragment activation of coagulation, fibrinolysis and kinin generation. J Clin Invest 1973; 52: 1402-409.

Mannucci PM Screening for hemostasis during hemorrhagic emergencies. Res Clin Lab 1989; 19:339-43.

Mammen E. , Koets MH , Washington B. et al. Hemostasis changes during cardiopulmonary bypass surgery. Thromb Haemost 1985; 11: 281-92.

Van de Starre , Van der Graaf , Griffin JB et al. Inhibition of the hypotensive effect of plasma protein solutions by C1-esterase inhibitor . J Thorac Cardiovasc Surg 1980; 79: 738-40.

10.

Cavarocchi NC , Pluth JR , Schaff HV et al. Complement activation during cardiopulmonary bypass. Comparison of bubble and membrane oxygenators. J Thorac Cardiovasc Surg 1986; 91: 252-58.

11.

Westaby S. , Turner MW , Stark J. Complement activation and anaphylactoid response to protamine in a child after cardiopulmonary bypass. Br Heart J 1985; 53: 574-76.

12.

Morel Dr , Zapol WM , Thomas SJ et al. C5a and thromboxane generation associated with pulmonary vaso- and bronchoconstriction during protamine reversal of heparin. Anesthesiology 1987; 66: 597-604.

C1-esterase inhibitor following cardiopulmonary bypass: evaluation of coagulation parameters - a preliminary report

Abstract

Get full access to this article

References